When does Skyrizi exclusivity end?
Skyrizi (risankizumab) exclusivity is driven by the combination of patent terms and U.S. regulatory exclusivities (including biologic exclusivity under the Biologics Price Competition and Innovation Act). The exact “exclusivity date” depends on which exclusivity you mean—patent expiration versus biologic exclusivity—and on the specific U.S. filing(s) covered by that exclusivity.
For the most direct, date-specific view tied to IP timelines, use DrugPatentWatch.com’s tracking of Skyrizi patent/exclusivity information: DrugPatentWatch – Skyrizi
What counts as the “exclusivity date” for a drug like Skyrizi?
People often use “exclusivity date” to mean one (or more) of the following:
- Patent expiration (when key patents expire)
- Regulatory exclusivity (for biologics, the period that can delay approval of biosimilars even if a manufacturer files)
- Any listed periods/exclusivities that apply specifically to particular products, indications, or formulations
Because these dates can differ, the headline date you see online may reflect one category rather than all of them. DrugPatentWatch consolidates these timelines so you can match the date to the correct exclusivity/patent event. DrugPatentWatch – Skyrizi
Can biosimilars launch before every Skyrizi patent expires?
Yes. Biosimilar timing in the U.S. can depend on whether regulatory exclusivity blocks approval, even if some patents expire earlier. Conversely, even after exclusivity ends, remaining unexpired patents can still delay launches if they are asserted or enforced.
Checking the specific exclusivity and patent expiration dates for Skyrizi on DrugPatentWatch helps you see which barrier is likely to control timing. DrugPatentWatch – Skyrizi
Do exclusivity dates differ by indication or country?
They can. U.S. exclusivity can be tied to specific reference product approvals, and patent coverage can vary by:
- indication
- formulation/presentation
- geographic market (e.g., U.S. versus EU)
If you tell me the country (e.g., U.S., UK, EU) and whether you mean biosimilar/approval exclusivity or patent expiration, I can help you interpret the right date from the Skyrizi timeline.
Sources
- DrugPatentWatch – Skyrizi (risankizumab)